Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist

被引:46
作者
Behm, DJ
Herold, CL
Ohlstein, EH
Knight, SD
Dhanak, D
Douglas, SA
机构
[1] GlaxoSmithKline, Cardiovasc & Urogenital Dis Ctr Excellence Drug D, Dept Vasc Biol, King Of Prussia, PA 19406 USA
[2] GlaxoSmithKline, Cardiovasc & Urogenital Dis Ctr Excellence Drug D, Dept Med Chem, King Of Prussia, PA 19406 USA
关键词
urotensin-II; GPR14; UT receptor; somatostatin; endothelin-1; vasoconstriction; vasorelaxation; sodium nitroprusside; carbachol; SB-710411;
D O I
10.1038/sj.bjp.0704887
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Human urotensin-II (hU-II), a cyclic undecapeptide, is amongst the most potent mammalian vasoconstrictors identified, suggesting that hU-II and its G-protein-coupled receptor (UT) may regulate cardiovascular homeostasis. Such a hypothesis would benefit greatly from the development of selective UT antagonists. 2 Although the somatostatin (SST) antagonist SB-710411 (Cpa-c[D-Cys-PaI-D-Trp-Lys-VaI-Cys]-Cpa-amide) is purported to block U-II-induced contractions in rat isolated aorta, little is known about its specific pharmacological properties. 3 SB-710411 (10 mum) inhibited hU-II-induced contraction in rat isolated aorta causing a significant, parallel shift in the agonist concentration-response curve (pK(b) 6.28 +/- 0.11; n = 8) with no suppression of the E-max. In contrast, SB-710411 did not alter the contractile actions of angiotensin-II, phenylephrine, or KCl. Paradoxically, however, SB-710411 potentiated the contractile response to endothelin-1 (pEC(50) 8.02 +/- 0.16 and 8.54 +/- 0.11, P<0.01; n = 8). Rather than being specific to SB-710411, this phenomenon appears to be related to somatostatin receptor affinity and not intrinsic activity since the SST agonist somatostatin-14 and antagonist cyclo-somatostatin also potentiated endothelin-1-induced contraction. 4 SB-710411 (10 pm) did not inhibit carbachol, sodium nitroprusside, IBMX, isoprenaline, and levcromakalim-induced reversal of tone established with noradrenaline. In contrast, however, SB-710411 significantly inhibited the reversal of tone established with endothelin-1 using the same vasorelaxants. 5 In summary, although SB-710411 inhibits the vasoconstrictor actions of hU-II in a competitive, surmountable manner, it also possesses additional pharmacological actions. Thus, whilst the present study is amongst the first to detail the properties of a functional U-II receptor antagonist, the data suggest caution be used when assessing data generated utilizing this moiety and other SST analogues.
引用
收藏
页码:449 / 458
页数:10
相关论文
共 23 条
  • [1] Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
    Ames, RS
    Sarau, HM
    Chambers, JK
    Willette, RN
    Alyar, NV
    Romanic, AM
    Louden, CS
    Foley, JJ
    Sauermelch, CF
    Coatney, RW
    Ao, ZH
    Disa, J
    Holmes, SD
    Stadel, JM
    Martin, JD
    Liu, WS
    Glover, GI
    Wilson, S
    McNulty, DE
    Ellis, CE
    Elshourbagy, NA
    Shabon, U
    Trill, JJ
    Hay, DWP
    Ohlstein, EH
    Bergsma, DJ
    Douglas, SA
    [J]. NATURE, 1999, 401 (6750) : 282 - 286
  • [2] BEHM DJ, 2001, PHARMACOLOGIST, V43, P190
  • [3] Urotensin II evokes potent vasoconstriction in humans in vivo
    Böhm, F
    Pernow, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) : 25 - 27
  • [4] Effects of human urotensin II in isolated vessels of various species;: comparison with other vasoactive agents
    Camarda, V
    Rizzi, A
    Calò, G
    Gendron, G
    Perron, SI
    Kostenis, E
    Zamboni, P
    Mascoli, F
    Regoli, D
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 (02) : 141 - 149
  • [5] Coy D. H., 2000, Regulatory Peptides, V94, P48, DOI 10.1016/S0167-0115(00)80097-X
  • [6] PHARMACOLOGICAL EVIDENCE FOR THE PRESENCE OF 3 DISTINCT FUNCTIONAL ENDOTHELIN RECEPTOR SUBTYPES IN THE RABBIT LATERAL SAPHENOUS-VEIN
    DOUGLAS, SA
    BECK, GR
    ELLIOTT, JD
    OHLSTEIN, EH
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (08) : 1529 - 1540
  • [7] Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease
    Douglas, SA
    Ohlstein, EH
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (06) : 229 - 237
  • [8] Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey
    Douglas, SA
    Sulpizio, AC
    Piercy, V
    Sarau, HM
    Ames, RS
    Aiyar, NV
    Ohlstein, EH
    Willette, RN
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (07) : 1262 - 1274
  • [9] DOUGLAS SA, 2000, IUPHAR COMPENDIUM RE, P365
  • [10] HEROLD CL, 2001, PHARMACOLOGIST, V43, P189